Key takeaway: Aarti Drugs Limited's Q1 FY27 investor presentation highlights strong operational and financial performance, with a 19% year-on-year (YoY) increase in total revenue to ₹702.8 crore, driven by volume growth and improved realizations in its API and Specialty Chemicals segments. EBITDA rose 30% YoY to ₹96.9 crore, with margins expanding by 120 basis points to 13.8%. The company reported a 35% YoY increase in PBT to ₹69.2 crore, though PAT declined 7% YoY to ₹50.1 crore due to tax adjustments. Management emphasized disciplined execution, pricing recovery, and operational efficiencies, supported by USFDA and UK approvals for facilities. Strategic initiatives include expanding production capacity through brownfield and greenfield projects, enhancing backward integration, and developing oncology and formulation capabilities. The company's diversified presence across 100+ countries, with Asia contributing 49% of sales, and a robust balance sheet with strong cash flows were noted. The presentation also outlined growth strategies, including a ₹200 crore investment in oncology development and a ₹600 crore capex for capacity expansion, aiming to improve margins and operating leverage. Historical financials showed consistent revenue growth and profitability, with net worth increasing to ₹1,549.2 crore as of March 2026.

Key takeaway: Aarti Drugs Limited held its Q4 FY26 earnings conference call on May 18, 2026, where management discussed the company's transition from an investment phase to operational scale-up. Despite facing macroeconomic challenges, including geopolitical uncertainties and elevated input costs, the company reported a revenue increase to INR721.1 crores for Q4 FY26, up 6% year-on-year and 20% quarter-on-quarter. EBITDA was INR96.6 crores, reflecting a 72% quarter-on-quarter growth. The stand-alone revenue was INR631.7 crores, with 63% from the domestic market. Management highlighted a strong performance in the formulation segment, particularly in exports, and noted a ramp-up in their new methylamines facility. They also discussed the impact of pricing trends stabilizing and the gradual shift towards regulated markets. Management set a goal of maintaining EBITDA margins between 13.5% to 14% for FY27, contingent on external factors like crude prices.

Key takeaway: Aarti Drugs Limited's investor presentation for Q4 and FY26 highlighted a total revenue of Rs. 721.1 crore for Q4 FY26, marking a 6% year-over-year increase. EBITDA was reported at Rs. 96.6 crore, with a margin of 13.4%, reflecting a decline of 60 basis points compared to the previous year. The presentation noted that the company's profitability was affected by start-up losses from new facilities and weakness in the domestic antibiotics market. However, sequentially, revenue and EBITDA improved by 20% and 72%, respectively. The management emphasized a shift towards regulated markets, with contributions increasing from 66% in FY25 to 73% in FY26. The company also reported a strong focus on expanding its product pipeline and enhancing operational capabilities, particularly in oncology and specialty chemicals. Overall, the presentation outlined the company's strategic initiatives and resilience amid industry challenges.

Key takeaway: Aarti Drugs Limited's Q3 FY26 investor presentation reported an 8% year-on-year increase in total revenue, reaching Rs. 602.9 crore, while EBITDA was Rs. 56.3 crore with a margin of 9.3%. The presentation highlighted a 58% increase in profit after tax (PAT) to Rs. 40.5 crore, with a PAT margin of 6.7%. Management noted that the domestic market showed healthy traction, and the export formulations segment performed well. The company is focusing on operational efficiency and capacity ramp-up, with significant progress in its backward integration projects. The Sayakha plant achieved 30% capacity utilization in its first quarter, and the Tarapur Salicylic Acid plant scaled to over 300 tonnes per month. Management emphasized ongoing regulatory compliance and the positive momentum in January sales, indicating a favorable trend for future quarters.